CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Microraft arrays for serial-killer CD19 chimeric antigen receptor T cells and single cell isolation.
Microraft arrays for serial-killer CD19 chimeric antigen receptor T cells and single cell isolation.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR-T(CAR-T)细胞免疫疗法近年来在治疗血液系统恶性肿瘤方面取得了成功;然而,其结果可能高度可变。单细胞异质性在CAR-T 细胞治疗疗效的可变性中起关键作用,但很大程度上尚未被探索。一个主要挑战是理解单个CAR-T 细胞的杀伤行为和表型,这些细胞能够连续杀伤靶细胞。
因此,一个能够测量时间依赖性CAR-T 细胞介导的杀伤,然后分离单细胞用于下游检测的平台,对于表征CAR-T 细胞将是无价的。设计了一个自动化microraft阵列平台,用于追踪CD19 CAR-T 细胞对CD19+靶细胞的杀伤以及CAR-T 细胞随时间的运动性,随后根据杀伤行为收集CAR-T 细胞。该平台展示了自动化CAR-T 细胞计数,特异性高达98%,灵敏度达96%,单细胞分离效率为89%。平均而言,2.3%的单个CAR-T 细胞被证明参与对靶细胞的连续杀伤,在6 h内最多杀伤三个靶细胞。在四个microraft阵列上追踪了>7000个单个CAR-T 细胞的细胞毒性和运动性。自动化microraft阵列平台测量了时间性细胞介导的细胞毒性、CAR-T 细胞运动性、CAR-T 细胞死亡以及CAR-T 细胞与靶细胞的距离,随后具备分选任何所需CAR-T 细胞的能力。该流程有可能进一步加深我们对基于T细胞的癌症免疫疗法的理解,并改进细胞治疗产品以改善患者结局。
Chimeric antigen receptor T (CAR-T) cell immunotherapies have seen success in treating hematological malignancies in recent years; however, the results can be highly variable. Single cell heterogeneity plays a key role in the variable efficacy of CAR-T cell treatments yet is largely unexplored. A major challenge is to understand the killing behavior and phenotype of individual CAR-T cells, which are able to serially kill targets.
Thus, a platform capable of measuring time-dependent CAR-T cell mediated killing and then isolating single cells for downstream assays would be invaluable in characterizing CAR-T cells. An automated microraft array platform was designed to track CD19 CAR-T cell killing of CD19+ target cells and CAR-T cell motility over time followed by CAR-T cell collection based on killing behavior. The platform demonstrated automated CAR-T cell counting with up to 98% specificity and 96% sensitivity, and single cells were isolated with 89% efficiency. On average, 2.
3% of single CAR-T cells were shown to participate in serial-killing of target cells, killing a maximum of three target cells in a 6 h period. The cytotoxicity and motility of >7000 individual CAR-T cells was tracked across four microraft arrays.
The automated microraft array platform measured temporal cell-mediated cytotoxicity, CAR-T cell motility, CAR-T cell death, and CAR-T cell to target cell distances, followed by the capability to sort any desired CAR-T cell. The pipeline has the potential to further our understanding of T cell-based cancer immunotherapies and improve cell-therapy products for better patient outcomes.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。